Asunto(s)
Hepatitis B Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Adolescente , Adulto , Antivirales/efectos adversos , Antivirales/uso terapéutico , Femenino , Antígenos e de la Hepatitis B/sangre , Humanos , Interferón alfa-2 , Interferón-alfa/efectos adversos , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas RecombinantesRESUMEN
This work was carried out to study the pattern of use of antimicrobial agents in Egypt. 2034 files were selected from two general hospitals by a systematic random sampling method, and the data concerning the antimicrobials were collected from each file. The results of this study showed that there was misuse of these agents both in therapy and prophylaxis. Antibiotics were prescribed to 80.17% of admitted patients. In most of the cases they were prescribed without documented proof of infection and were prescribed for conditions in which antimicrobial use is not justified for either therapy or prophylaxis. Among patients who received antibiotics, 30.8% received repeated courses, in most of whom there was no reasonable indication.
Asunto(s)
Antibacterianos/administración & dosificación , Utilización de Medicamentos/tendencias , Egipto , Hospitales Generales , Humanos , PremedicaciónRESUMEN
Twenty patients with documented chronic active hepatitis B were randomized in equal numbers to either an alpha-2b interferon treatment group or a control group with no treatment. Patients in the first group received 5 IU interferon three times weekly by subcutaneous injection for 16 weeks. All 20 patients were HBeAg positive at the beginning. All 10 patients in the interferon-treated group lost their initial e antigen while only 2 patients in the control group turned HBeAg negative. Six patients in the treated group acquired HBe antibodies in comparison with two patients only in the untreated group. Other markers of suppression of viral replication as well as a 24-month follow-up are ongoing at the moment for final assessment of the value of interferon therapy in chronic active hepatitis B.